Dr. Erdal Diri
Claim this profileGSK Investigational Site
Studies Arthritis
Studies Rheumatoid Arthritis
7 reported clinical trials
12 drugs studied
Affiliated Hospitals
Clinical Trials Erdal Diri is currently running
Baricitinib
for Rheumatoid Arthritis
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.
Recruiting3 awards Phase 43 criteria
Belimumab
for Lupus
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.
Recruiting3 awards Phase 43 criteria
More about Erdal Diri
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Erdal Diri has experience with
- Tildrakizumab
- Matching Placebo Injections
- Olokizumab
- GSK3196165 (Otilimab)
- Tofacitinib
- Placebo To GSK3196165 (Otilimab)
Breakdown of trials Erdal Diri has run
Arthritis
- Baricitinib for Rheumatoid Arthritis
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
Rheumatoid Arthritis
- Baricitinib for Rheumatoid Arthritis
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
Psoriatic Arthritis
Systemic Lupus Erythematosus
Lupus
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Erdal Diri specialize in?
Erdal Diri focuses on Arthritis and Rheumatoid Arthritis. In particular, much of their work with Arthritis has involved treating patients, or patients who are undergoing treatment.
Is Erdal Diri currently recruiting for clinical trials?
Yes, Erdal Diri is currently recruiting for 3 clinical trials in Minot North Dakota. If you're interested in participating, you should apply.
Are there any treatments that Erdal Diri has studied deeply?
Yes, Erdal Diri has studied treatments such as Tildrakizumab, Matching Placebo Injections, Olokizumab.
What is the best way to schedule an appointment with Erdal Diri?
Apply for one of the trials that Erdal Diri is conducting.
What is the office address of Erdal Diri?
The office of Erdal Diri is located at: GSK Investigational Site, Minot, North Dakota 58701 United States. This is the address for their practice at the GSK Investigational Site.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.